Mar 5, 2026 08:31AM
Mar 5, 2026 08:30AM
Feb 25, 2026 06:30AM
Dec 8, 2025 07:30AM
Dec 8, 2025 07:30AM
Dec 8, 2025 07:30AM
Dec 8, 2025 07:30AM Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Nov 18, 2025 08:45AM
Sep 8, 2025 07:01AM
Jul 28, 2025 07:00AM
Jun 4, 2025 02:36PM
May 4, 2025 12:45PM
Apr 29, 2025 08:45AM
Apr 22, 2025 08:34PM Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
Mar 18, 2025 08:03AM
Mar 18, 2025 08:00AM
Feb 5, 2025 05:27PM
Feb 5, 2025 05:24PM
Jan 7, 2025 09:15AM
Jan 7, 2025 09:15AM
Jan 7, 2025 09:15AM Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
Dec 4, 2024 08:45AM
Nov 6, 2024 04:15PM
Oct 2, 2024 02:17PM
Oct 2, 2024 08:02AM
Oct 2, 2024 08:00AM
Sep 3, 2024 03:00PM
Sep 3, 2024 02:54PM TD Cowen Reiterates Hold Rating on Recursion Pharmaceuticals (RXRX )
Sep 3, 2024 11:50AM
Sep 3, 2024 08:19AM
Sep 3, 2024 08:00AM
Sep 3, 2024 08:00AM
Aug 8, 2023 07:58AM
Jun 13, 2023 08:00AM
Sep 13, 2022 07:59AM Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
Aug 9, 2022 04:15PM
Jul 21, 2022 07:55AM
Jul 21, 2022 07:55AM
Jun 20, 2022 07:55AM
May 10, 2022 04:29PM
Apr 11, 2022 07:55AM
Apr 11, 2022 07:55AM Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Mar 23, 2022 07:55AM
Mar 23, 2022 07:55AM
Mar 18, 2022 07:55AM
Nov 10, 2021 07:55AM
Oct 7, 2021 07:56AM
Oct 7, 2021 07:55AM
Sep 29, 2021 08:55AM Recursion Pharmaceuticals (RXRX) Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Sep 29, 2021 08:54AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All